nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—ALB—multiple sclerosis	0.299	1	CbGaD
Enzalutamide—CYP2D6—Fingolimod—multiple sclerosis	0.0507	0.0966	CbGbCtD
Enzalutamide—ALB—Prednisone—multiple sclerosis	0.0401	0.0765	CbGbCtD
Enzalutamide—ABCB1—Methylprednisolone—multiple sclerosis	0.0347	0.0661	CbGbCtD
Enzalutamide—CYP3A4—Fingolimod—multiple sclerosis	0.0322	0.0614	CbGbCtD
Enzalutamide—CYP2C19—Prednisone—multiple sclerosis	0.026	0.0496	CbGbCtD
Enzalutamide—CYP2B6—Dexamethasone—multiple sclerosis	0.0256	0.0487	CbGbCtD
Enzalutamide—ABCB1—Mitoxantrone—multiple sclerosis	0.0253	0.0482	CbGbCtD
Enzalutamide—ABCB1—Betamethasone—multiple sclerosis	0.0225	0.0429	CbGbCtD
Enzalutamide—ABCB1—Prednisolone—multiple sclerosis	0.0222	0.0424	CbGbCtD
Enzalutamide—ABCB1—Prednisone—multiple sclerosis	0.021	0.04	CbGbCtD
Enzalutamide—CYP3A4—Methylprednisolone—multiple sclerosis	0.0208	0.0396	CbGbCtD
Enzalutamide—CYP3A5—Dexamethasone—multiple sclerosis	0.0201	0.0384	CbGbCtD
Enzalutamide—ALB—Methotrexate—multiple sclerosis	0.0201	0.0384	CbGbCtD
Enzalutamide—CYP2C8—Dexamethasone—multiple sclerosis	0.0194	0.0369	CbGbCtD
Enzalutamide—CYP2C19—Dexamethasone—multiple sclerosis	0.0162	0.031	CbGbCtD
Enzalutamide—CYP3A4—Triamcinolone—multiple sclerosis	0.0157	0.03	CbGbCtD
Enzalutamide—CYP3A4—Mitoxantrone—multiple sclerosis	0.0151	0.0289	CbGbCtD
Enzalutamide—CYP2C9—Dexamethasone—multiple sclerosis	0.0135	0.0257	CbGbCtD
Enzalutamide—CYP3A4—Betamethasone—multiple sclerosis	0.0135	0.0257	CbGbCtD
Enzalutamide—CYP3A4—Prednisolone—multiple sclerosis	0.0133	0.0254	CbGbCtD
Enzalutamide—ABCB1—Dexamethasone—multiple sclerosis	0.0131	0.025	CbGbCtD
Enzalutamide—CYP3A4—Prednisone—multiple sclerosis	0.0126	0.024	CbGbCtD
Enzalutamide—CYP2D6—Dexamethasone—multiple sclerosis	0.0124	0.0235	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—multiple sclerosis	0.0105	0.0201	CbGbCtD
Enzalutamide—CYP3A4—Dexamethasone—multiple sclerosis	0.00785	0.015	CbGbCtD
Enzalutamide—Cognitive disorder—Methotrexate—multiple sclerosis	0.00116	0.00845	CcSEcCtD
Enzalutamide—Back pain—Fingolimod—multiple sclerosis	0.00115	0.00832	CcSEcCtD
Enzalutamide—Leukopenia—Fingolimod—multiple sclerosis	0.00106	0.0077	CcSEcCtD
Enzalutamide—Fracture—Prednisone—multiple sclerosis	0.00104	0.00752	CcSEcCtD
Enzalutamide—Multiple fractures—Prednisone—multiple sclerosis	0.00104	0.00752	CcSEcCtD
Enzalutamide—Hypertension—Fingolimod—multiple sclerosis	0.00102	0.00743	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.001	0.00727	CcSEcCtD
Enzalutamide—Muscular weakness—Cladribine—multiple sclerosis	0.000983	0.00714	CcSEcCtD
Enzalutamide—Infection—Fingolimod—multiple sclerosis	0.00096	0.00697	CcSEcCtD
Enzalutamide—Nervous system disorder—Fingolimod—multiple sclerosis	0.000948	0.00688	CcSEcCtD
Enzalutamide—Skin disorder—Fingolimod—multiple sclerosis	0.000939	0.00682	CcSEcCtD
Enzalutamide—Neutropenia—Cladribine—multiple sclerosis	0.000901	0.00654	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Cladribine—multiple sclerosis	0.000896	0.0065	CcSEcCtD
Enzalutamide—Sepsis—Mitoxantrone—multiple sclerosis	0.000876	0.00636	CcSEcCtD
Enzalutamide—Paraesthesia—Fingolimod—multiple sclerosis	0.000868	0.0063	CcSEcCtD
Enzalutamide—Multiple fractures—Methotrexate—multiple sclerosis	0.000865	0.00629	CcSEcCtD
Enzalutamide—Fracture—Methotrexate—multiple sclerosis	0.000865	0.00629	CcSEcCtD
Enzalutamide—Pneumonia—Cladribine—multiple sclerosis	0.000864	0.00628	CcSEcCtD
Enzalutamide—Infestation NOS—Cladribine—multiple sclerosis	0.000859	0.00624	CcSEcCtD
Enzalutamide—Infestation—Cladribine—multiple sclerosis	0.000859	0.00624	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.000834	0.00606	CcSEcCtD
Enzalutamide—Fatigue—Fingolimod—multiple sclerosis	0.000833	0.00605	CcSEcCtD
Enzalutamide—Epistaxis—Cladribine—multiple sclerosis	0.00081	0.00589	CcSEcCtD
Enzalutamide—Memory impairment—Prednisone—multiple sclerosis	0.000767	0.00557	CcSEcCtD
Enzalutamide—Pharyngitis—Cladribine—multiple sclerosis	0.000765	0.00556	CcSEcCtD
Enzalutamide—Urinary tract disorder—Cladribine—multiple sclerosis	0.000762	0.00553	CcSEcCtD
Enzalutamide—Oedema peripheral—Cladribine—multiple sclerosis	0.00076	0.00552	CcSEcCtD
Enzalutamide—Connective tissue disorder—Cladribine—multiple sclerosis	0.000758	0.0055	CcSEcCtD
Enzalutamide—Urethral disorder—Cladribine—multiple sclerosis	0.000756	0.00549	CcSEcCtD
Enzalutamide—Pneumonia—Azathioprine—multiple sclerosis	0.000703	0.0051	CcSEcCtD
Enzalutamide—Angiopathy—Cladribine—multiple sclerosis	0.0007	0.00508	CcSEcCtD
Enzalutamide—Infestation NOS—Azathioprine—multiple sclerosis	0.000699	0.00507	CcSEcCtD
Enzalutamide—Infestation—Azathioprine—multiple sclerosis	0.000699	0.00507	CcSEcCtD
Enzalutamide—Asthenia—Fingolimod—multiple sclerosis	0.000694	0.00504	CcSEcCtD
Enzalutamide—Pruritus—Fingolimod—multiple sclerosis	0.000684	0.00497	CcSEcCtD
Enzalutamide—Mental disorder—Cladribine—multiple sclerosis	0.000676	0.00491	CcSEcCtD
Enzalutamide—Diarrhoea—Fingolimod—multiple sclerosis	0.000661	0.0048	CcSEcCtD
Enzalutamide—Injury—Prednisolone—multiple sclerosis	0.000654	0.00475	CcSEcCtD
Enzalutamide—Back pain—Cladribine—multiple sclerosis	0.000649	0.00472	CcSEcCtD
Enzalutamide—Dizziness—Fingolimod—multiple sclerosis	0.000639	0.00464	CcSEcCtD
Enzalutamide—Headache—Fingolimod—multiple sclerosis	0.000606	0.0044	CcSEcCtD
Enzalutamide—Injury—Triamcinolone—multiple sclerosis	0.000601	0.00437	CcSEcCtD
Enzalutamide—Injury—Methylprednisolone—multiple sclerosis	0.0006	0.00436	CcSEcCtD
Enzalutamide—Neutropenia—Mitoxantrone—multiple sclerosis	0.000592	0.0043	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Mitoxantrone—multiple sclerosis	0.000589	0.00427	CcSEcCtD
Enzalutamide—Amnesia—Methylprednisolone—multiple sclerosis	0.000587	0.00426	CcSEcCtD
Enzalutamide—Arthralgia—Cladribine—multiple sclerosis	0.000572	0.00415	CcSEcCtD
Enzalutamide—Anxiety—Cladribine—multiple sclerosis	0.00057	0.00414	CcSEcCtD
Enzalutamide—Pneumonia—Mitoxantrone—multiple sclerosis	0.000568	0.00413	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.000568	0.00412	CcSEcCtD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—multiple sclerosis	0.000561	0.00407	CcSEcCtD
Enzalutamide—Dry skin—Prednisolone—multiple sclerosis	0.000551	0.004	CcSEcCtD
Enzalutamide—Injury—Dexamethasone—multiple sclerosis	0.000546	0.00396	CcSEcCtD
Enzalutamide—Injury—Betamethasone—multiple sclerosis	0.000546	0.00396	CcSEcCtD
Enzalutamide—Infection—Cladribine—multiple sclerosis	0.000544	0.00395	CcSEcCtD
Enzalutamide—Haematuria—Mitoxantrone—multiple sclerosis	0.000538	0.00391	CcSEcCtD
Enzalutamide—Nervous system disorder—Cladribine—multiple sclerosis	0.000537	0.0039	CcSEcCtD
Enzalutamide—Thrombocytopenia—Cladribine—multiple sclerosis	0.000536	0.0039	CcSEcCtD
Enzalutamide—Skin disorder—Cladribine—multiple sclerosis	0.000532	0.00387	CcSEcCtD
Enzalutamide—Muscular weakness—Prednisolone—multiple sclerosis	0.00053	0.00385	CcSEcCtD
Enzalutamide—Sinusitis—Mitoxantrone—multiple sclerosis	0.00053	0.00385	CcSEcCtD
Enzalutamide—Sepsis—Prednisone—multiple sclerosis	0.000522	0.00379	CcSEcCtD
Enzalutamide—Rhinitis—Mitoxantrone—multiple sclerosis	0.000508	0.00369	CcSEcCtD
Enzalutamide—Pharyngitis—Mitoxantrone—multiple sclerosis	0.000503	0.00365	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000499	0.00363	CcSEcCtD
Enzalutamide—Insomnia—Cladribine—multiple sclerosis	0.000496	0.0036	CcSEcCtD
Enzalutamide—Paraesthesia—Cladribine—multiple sclerosis	0.000492	0.00357	CcSEcCtD
Enzalutamide—Leukopenia—Azathioprine—multiple sclerosis	0.000489	0.00355	CcSEcCtD
Enzalutamide—Muscular weakness—Triamcinolone—multiple sclerosis	0.000488	0.00354	CcSEcCtD
Enzalutamide—Muscular weakness—Methylprednisolone—multiple sclerosis	0.000487	0.00353	CcSEcCtD
Enzalutamide—Injury—Prednisone—multiple sclerosis	0.000475	0.00345	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000473	0.00344	CcSEcCtD
Enzalutamide—Fatigue—Cladribine—multiple sclerosis	0.000472	0.00343	CcSEcCtD
Enzalutamide—Amnesia—Prednisone—multiple sclerosis	0.000465	0.00338	CcSEcCtD
Enzalutamide—Arthralgia—Azathioprine—multiple sclerosis	0.000465	0.00338	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000462	0.00335	CcSEcCtD
Enzalutamide—Dry skin—Betamethasone—multiple sclerosis	0.00046	0.00334	CcSEcCtD
Enzalutamide—Dry skin—Dexamethasone—multiple sclerosis	0.00046	0.00334	CcSEcCtD
Enzalutamide—Bronchitis—Triamcinolone—multiple sclerosis	0.00046	0.00334	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Triamcinolone—multiple sclerosis	0.000444	0.00323	CcSEcCtD
Enzalutamide—Infection—Azathioprine—multiple sclerosis	0.000443	0.00321	CcSEcCtD
Enzalutamide—Muscular weakness—Dexamethasone—multiple sclerosis	0.000442	0.00321	CcSEcCtD
Enzalutamide—Muscular weakness—Betamethasone—multiple sclerosis	0.000442	0.00321	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—multiple sclerosis	0.000436	0.00317	CcSEcCtD
Enzalutamide—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000436	0.00317	CcSEcCtD
Enzalutamide—Skin disorder—Azathioprine—multiple sclerosis	0.000433	0.00314	CcSEcCtD
Enzalutamide—Back pain—Mitoxantrone—multiple sclerosis	0.000427	0.0031	CcSEcCtD
Enzalutamide—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000425	0.00309	CcSEcCtD
Enzalutamide—Infestation—Methylprednisolone—multiple sclerosis	0.000425	0.00309	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.000406	0.00295	CcSEcCtD
Enzalutamide—Epistaxis—Triamcinolone—multiple sclerosis	0.000402	0.00292	CcSEcCtD
Enzalutamide—Dry skin—Prednisone—multiple sclerosis	0.0004	0.00291	CcSEcCtD
Enzalutamide—Leukopenia—Mitoxantrone—multiple sclerosis	0.000395	0.00287	CcSEcCtD
Enzalutamide—Asthenia—Cladribine—multiple sclerosis	0.000393	0.00286	CcSEcCtD
Enzalutamide—Pruritus—Cladribine—multiple sclerosis	0.000388	0.00282	CcSEcCtD
Enzalutamide—Muscular weakness—Prednisone—multiple sclerosis	0.000385	0.0028	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000385	0.00279	CcSEcCtD
Enzalutamide—Rhinitis—Triamcinolone—multiple sclerosis	0.000383	0.00278	CcSEcCtD
Enzalutamide—Rhinitis—Methylprednisolone—multiple sclerosis	0.000383	0.00278	CcSEcCtD
Enzalutamide—Convulsion—Mitoxantrone—multiple sclerosis	0.000382	0.00278	CcSEcCtD
Enzalutamide—Hypertension—Mitoxantrone—multiple sclerosis	0.000381	0.00277	CcSEcCtD
Enzalutamide—Pharyngitis—Triamcinolone—multiple sclerosis	0.00038	0.00276	CcSEcCtD
Enzalutamide—Arthralgia—Mitoxantrone—multiple sclerosis	0.000376	0.00273	CcSEcCtD
Enzalutamide—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000375	0.00272	CcSEcCtD
Enzalutamide—Diarrhoea—Cladribine—multiple sclerosis	0.000375	0.00272	CcSEcCtD
Enzalutamide—Anxiety—Mitoxantrone—multiple sclerosis	0.000374	0.00272	CcSEcCtD
Enzalutamide—Dizziness—Cladribine—multiple sclerosis	0.000362	0.00263	CcSEcCtD
Enzalutamide—Infection—Mitoxantrone—multiple sclerosis	0.000358	0.0026	CcSEcCtD
Enzalutamide—Neutropenia—Prednisone—multiple sclerosis	0.000353	0.00256	CcSEcCtD
Enzalutamide—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000353	0.00256	CcSEcCtD
Enzalutamide—Skin disorder—Mitoxantrone—multiple sclerosis	0.00035	0.00254	CcSEcCtD
Enzalutamide—Angiopathy—Methylprednisolone—multiple sclerosis	0.000346	0.00251	CcSEcCtD
Enzalutamide—Headache—Cladribine—multiple sclerosis	0.000343	0.00249	CcSEcCtD
Enzalutamide—Mental disorder—Methylprednisolone—multiple sclerosis	0.000334	0.00243	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000328	0.00238	CcSEcCtD
Enzalutamide—Vertigo—Prednisolone—multiple sclerosis	0.000325	0.00236	CcSEcCtD
Enzalutamide—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000323	0.00235	CcSEcCtD
Enzalutamide—Back pain—Triamcinolone—multiple sclerosis	0.000322	0.00234	CcSEcCtD
Enzalutamide—Angiopathy—Dexamethasone—multiple sclerosis	0.000315	0.00229	CcSEcCtD
Enzalutamide—Angiopathy—Betamethasone—multiple sclerosis	0.000315	0.00229	CcSEcCtD
Enzalutamide—Convulsion—Prednisolone—multiple sclerosis	0.000314	0.00228	CcSEcCtD
Enzalutamide—Hypertension—Prednisolone—multiple sclerosis	0.000313	0.00227	CcSEcCtD
Enzalutamide—Fatigue—Mitoxantrone—multiple sclerosis	0.000311	0.00226	CcSEcCtD
Enzalutamide—Diarrhoea—Azathioprine—multiple sclerosis	0.000305	0.00221	CcSEcCtD
Enzalutamide—Vertigo—Triamcinolone—multiple sclerosis	0.000299	0.00217	CcSEcCtD
Enzalutamide—Vertigo—Methylprednisolone—multiple sclerosis	0.000298	0.00217	CcSEcCtD
Enzalutamide—Connective tissue disorder—Prednisone—multiple sclerosis	0.000297	0.00216	CcSEcCtD
Enzalutamide—Neutropenia—Methotrexate—multiple sclerosis	0.000295	0.00214	CcSEcCtD
Enzalutamide—Dizziness—Azathioprine—multiple sclerosis	0.000295	0.00214	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—multiple sclerosis	0.000293	0.00213	CcSEcCtD
Enzalutamide—Convulsion—Triamcinolone—multiple sclerosis	0.000288	0.0021	CcSEcCtD
Enzalutamide—Convulsion—Methylprednisolone—multiple sclerosis	0.000288	0.00209	CcSEcCtD
Enzalutamide—Hypertension—Triamcinolone—multiple sclerosis	0.000287	0.00209	CcSEcCtD
Enzalutamide—Hypertension—Methylprednisolone—multiple sclerosis	0.000287	0.00208	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—multiple sclerosis	0.000283	0.00206	CcSEcCtD
Enzalutamide—Arthralgia—Methylprednisolone—multiple sclerosis	0.000283	0.00205	CcSEcCtD
Enzalutamide—Anxiety—Methylprednisolone—multiple sclerosis	0.000282	0.00205	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—multiple sclerosis	0.000281	0.00204	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—multiple sclerosis	0.000281	0.00204	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000281	0.00204	CcSEcCtD
Enzalutamide—Headache—Azathioprine—multiple sclerosis	0.000279	0.00203	CcSEcCtD
Enzalutamide—Angiopathy—Prednisone—multiple sclerosis	0.000274	0.00199	CcSEcCtD
Enzalutamide—Vertigo—Betamethasone—multiple sclerosis	0.000271	0.00197	CcSEcCtD
Enzalutamide—Vertigo—Dexamethasone—multiple sclerosis	0.000271	0.00197	CcSEcCtD
Enzalutamide—Infection—Triamcinolone—multiple sclerosis	0.00027	0.00196	CcSEcCtD
Enzalutamide—Infection—Methylprednisolone—multiple sclerosis	0.000269	0.00196	CcSEcCtD
Enzalutamide—Haematuria—Methotrexate—multiple sclerosis	0.000268	0.00195	CcSEcCtD
Enzalutamide—Insomnia—Prednisolone—multiple sclerosis	0.000267	0.00194	CcSEcCtD
Enzalutamide—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000266	0.00193	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—multiple sclerosis	0.000265	0.00193	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisolone—multiple sclerosis	0.000265	0.00193	CcSEcCtD
Enzalutamide—Mental disorder—Prednisone—multiple sclerosis	0.000265	0.00192	CcSEcCtD
Enzalutamide—Skin disorder—Methylprednisolone—multiple sclerosis	0.000263	0.00191	CcSEcCtD
Enzalutamide—Convulsion—Dexamethasone—multiple sclerosis	0.000262	0.0019	CcSEcCtD
Enzalutamide—Convulsion—Betamethasone—multiple sclerosis	0.000262	0.0019	CcSEcCtD
Enzalutamide—Hypertension—Dexamethasone—multiple sclerosis	0.000261	0.00189	CcSEcCtD
Enzalutamide—Hypertension—Betamethasone—multiple sclerosis	0.000261	0.00189	CcSEcCtD
Enzalutamide—Asthenia—Mitoxantrone—multiple sclerosis	0.000258	0.00188	CcSEcCtD
Enzalutamide—Anxiety—Betamethasone—multiple sclerosis	0.000256	0.00186	CcSEcCtD
Enzalutamide—Anxiety—Dexamethasone—multiple sclerosis	0.000256	0.00186	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—multiple sclerosis	0.000251	0.00182	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000249	0.00181	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—multiple sclerosis	0.000248	0.0018	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000248	0.0018	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000247	0.00179	CcSEcCtD
Enzalutamide—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000246	0.00179	CcSEcCtD
Enzalutamide—Insomnia—Triamcinolone—multiple sclerosis	0.000246	0.00178	CcSEcCtD
Enzalutamide—Insomnia—Methylprednisolone—multiple sclerosis	0.000245	0.00178	CcSEcCtD
Enzalutamide—Infection—Dexamethasone—multiple sclerosis	0.000245	0.00178	CcSEcCtD
Enzalutamide—Infection—Betamethasone—multiple sclerosis	0.000245	0.00178	CcSEcCtD
Enzalutamide—Paraesthesia—Triamcinolone—multiple sclerosis	0.000244	0.00177	CcSEcCtD
Enzalutamide—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000243	0.00177	CcSEcCtD
Enzalutamide—Nervous system disorder—Betamethasone—multiple sclerosis	0.000242	0.00176	CcSEcCtD
Enzalutamide—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000242	0.00176	CcSEcCtD
Enzalutamide—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000241	0.00175	CcSEcCtD
Enzalutamide—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000241	0.00175	CcSEcCtD
Enzalutamide—Vertigo—Prednisone—multiple sclerosis	0.000236	0.00172	CcSEcCtD
Enzalutamide—Fatigue—Triamcinolone—multiple sclerosis	0.000234	0.0017	CcSEcCtD
Enzalutamide—Fatigue—Methylprednisolone—multiple sclerosis	0.000234	0.0017	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—multiple sclerosis	0.000229	0.00166	CcSEcCtD
Enzalutamide—Convulsion—Prednisone—multiple sclerosis	0.000228	0.00166	CcSEcCtD
Enzalutamide—Hypertension—Prednisone—multiple sclerosis	0.000227	0.00165	CcSEcCtD
Enzalutamide—Headache—Mitoxantrone—multiple sclerosis	0.000226	0.00164	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000225	0.00163	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000225	0.00163	CcSEcCtD
Enzalutamide—Arthralgia—Prednisone—multiple sclerosis	0.000224	0.00163	CcSEcCtD
Enzalutamide—Anxiety—Prednisone—multiple sclerosis	0.000223	0.00162	CcSEcCtD
Enzalutamide—Insomnia—Dexamethasone—multiple sclerosis	0.000223	0.00162	CcSEcCtD
Enzalutamide—Insomnia—Betamethasone—multiple sclerosis	0.000223	0.00162	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000222	0.00162	CcSEcCtD
Enzalutamide—Paraesthesia—Dexamethasone—multiple sclerosis	0.000221	0.00161	CcSEcCtD
Enzalutamide—Paraesthesia—Betamethasone—multiple sclerosis	0.000221	0.00161	CcSEcCtD
Enzalutamide—Mental disorder—Methotrexate—multiple sclerosis	0.000221	0.00161	CcSEcCtD
Enzalutamide—Infection—Prednisone—multiple sclerosis	0.000213	0.00155	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000213	0.00155	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000213	0.00155	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—multiple sclerosis	0.000213	0.00154	CcSEcCtD
Enzalutamide—Fatigue—Dexamethasone—multiple sclerosis	0.000213	0.00154	CcSEcCtD
Enzalutamide—Fatigue—Betamethasone—multiple sclerosis	0.000213	0.00154	CcSEcCtD
Enzalutamide—Nervous system disorder—Prednisone—multiple sclerosis	0.000211	0.00153	CcSEcCtD
Enzalutamide—Skin disorder—Prednisone—multiple sclerosis	0.000209	0.00151	CcSEcCtD
Enzalutamide—Vertigo—Methotrexate—multiple sclerosis	0.000198	0.00143	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—multiple sclerosis	0.000197	0.00143	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000196	0.00142	CcSEcCtD
Enzalutamide—Dizziness—Prednisolone—multiple sclerosis	0.000195	0.00142	CcSEcCtD
Enzalutamide—Asthenia—Triamcinolone—multiple sclerosis	0.000195	0.00142	CcSEcCtD
Enzalutamide—Asthenia—Methylprednisolone—multiple sclerosis	0.000195	0.00141	CcSEcCtD
Enzalutamide—Insomnia—Prednisone—multiple sclerosis	0.000194	0.00141	CcSEcCtD
Enzalutamide—Paraesthesia—Prednisone—multiple sclerosis	0.000193	0.0014	CcSEcCtD
Enzalutamide—Pruritus—Triamcinolone—multiple sclerosis	0.000192	0.0014	CcSEcCtD
Enzalutamide—Pruritus—Methylprednisolone—multiple sclerosis	0.000192	0.00139	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—multiple sclerosis	0.00019	0.00138	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—multiple sclerosis	0.000187	0.00136	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000186	0.00135	CcSEcCtD
Enzalutamide—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000186	0.00135	CcSEcCtD
Enzalutamide—Fatigue—Prednisone—multiple sclerosis	0.000185	0.00134	CcSEcCtD
Enzalutamide—Headache—Prednisolone—multiple sclerosis	0.000185	0.00134	CcSEcCtD
Enzalutamide—Dizziness—Triamcinolone—multiple sclerosis	0.00018	0.0013	CcSEcCtD
Enzalutamide—Dizziness—Methylprednisolone—multiple sclerosis	0.000179	0.0013	CcSEcCtD
Enzalutamide—Infection—Methotrexate—multiple sclerosis	0.000178	0.00129	CcSEcCtD
Enzalutamide—Asthenia—Dexamethasone—multiple sclerosis	0.000177	0.00128	CcSEcCtD
Enzalutamide—Asthenia—Betamethasone—multiple sclerosis	0.000177	0.00128	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—multiple sclerosis	0.000176	0.00128	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000176	0.00128	CcSEcCtD
Enzalutamide—Pruritus—Dexamethasone—multiple sclerosis	0.000174	0.00127	CcSEcCtD
Enzalutamide—Pruritus—Betamethasone—multiple sclerosis	0.000174	0.00127	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—multiple sclerosis	0.000174	0.00127	CcSEcCtD
Enzalutamide—Headache—Triamcinolone—multiple sclerosis	0.00017	0.00124	CcSEcCtD
Enzalutamide—Headache—Methylprednisolone—multiple sclerosis	0.00017	0.00123	CcSEcCtD
Enzalutamide—Diarrhoea—Betamethasone—multiple sclerosis	0.000169	0.00123	CcSEcCtD
Enzalutamide—Diarrhoea—Dexamethasone—multiple sclerosis	0.000169	0.00123	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000163	0.00119	CcSEcCtD
Enzalutamide—Dizziness—Betamethasone—multiple sclerosis	0.000163	0.00118	CcSEcCtD
Enzalutamide—Dizziness—Dexamethasone—multiple sclerosis	0.000163	0.00118	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—multiple sclerosis	0.000162	0.00118	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—multiple sclerosis	0.000161	0.00117	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000155	0.00113	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—multiple sclerosis	0.000155	0.00112	CcSEcCtD
Enzalutamide—Headache—Betamethasone—multiple sclerosis	0.000154	0.00112	CcSEcCtD
Enzalutamide—Headache—Dexamethasone—multiple sclerosis	0.000154	0.00112	CcSEcCtD
Enzalutamide—Asthenia—Prednisone—multiple sclerosis	0.000154	0.00112	CcSEcCtD
Enzalutamide—Pruritus—Prednisone—multiple sclerosis	0.000152	0.0011	CcSEcCtD
Enzalutamide—Diarrhoea—Prednisone—multiple sclerosis	0.000147	0.00107	CcSEcCtD
Enzalutamide—Dizziness—Prednisone—multiple sclerosis	0.000142	0.00103	CcSEcCtD
Enzalutamide—Headache—Prednisone—multiple sclerosis	0.000135	0.000977	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—multiple sclerosis	0.000129	0.000935	CcSEcCtD
Enzalutamide—Pruritus—Methotrexate—multiple sclerosis	0.000127	0.000922	CcSEcCtD
Enzalutamide—Diarrhoea—Methotrexate—multiple sclerosis	0.000123	0.000892	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—multiple sclerosis	0.000119	0.000862	CcSEcCtD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000117	0.00303	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000117	0.00302	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000117	0.00302	CbGpPWpGaD
Enzalutamide—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000116	0.003	CbGpPWpGaD
Enzalutamide—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000116	0.003	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000115	0.00298	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000115	0.00298	CbGpPWpGaD
Enzalutamide—Headache—Methotrexate—multiple sclerosis	0.000112	0.000816	CcSEcCtD
Enzalutamide—AR—SIDS Susceptibility Pathways—BDNF—multiple sclerosis	0.000111	0.00286	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.00011	0.00285	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL17A—multiple sclerosis	0.000109	0.00282	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CD28—multiple sclerosis	0.000106	0.00274	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL10—multiple sclerosis	0.000106	0.00273	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—ZNF746—multiple sclerosis	0.000105	0.00271	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL12B—multiple sclerosis	0.000101	0.00262	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-DPB1—multiple sclerosis	0.000101	0.0026	CbGpPWpGaD
Enzalutamide—ALB—Lipid and lipoprotein metabolism—APOE—multiple sclerosis	0.0001	0.0026	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—APOE—multiple sclerosis	9.88e-05	0.00255	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CD40—multiple sclerosis	9.68e-05	0.0025	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PTBP1—multiple sclerosis	9.58e-05	0.00248	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CTLA4—multiple sclerosis	9.54e-05	0.00246	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—PLEK—multiple sclerosis	9.52e-05	0.00246	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IL4—multiple sclerosis	9.51e-05	0.00246	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	9.41e-05	0.00243	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	9.28e-05	0.0024	CbGpPWpGaD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	9.22e-05	0.00238	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—multiple sclerosis	8.91e-05	0.0023	CbGpPWpGaD
Enzalutamide—CYP2B6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.86e-05	0.00229	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	8.72e-05	0.00225	CbGpPWpGaD
Enzalutamide—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.66e-05	0.00224	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	8.4e-05	0.00217	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	8.36e-05	0.00216	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—CCL2—multiple sclerosis	8.31e-05	0.00215	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.05e-05	0.00208	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SELPLG—multiple sclerosis	7.94e-05	0.00205	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—MERTK—multiple sclerosis	7.94e-05	0.00205	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—CD58—multiple sclerosis	7.94e-05	0.00205	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	7.85e-05	0.00203	CbGpPWpGaD
Enzalutamide—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	7.71e-05	0.00199	CbGpPWpGaD
Enzalutamide—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	7.71e-05	0.00199	CbGpPWpGaD
Enzalutamide—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	7.6e-05	0.00196	CbGpPWpGaD
Enzalutamide—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	7.6e-05	0.00196	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CD86—multiple sclerosis	7.56e-05	0.00195	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—ICAM1—multiple sclerosis	7.55e-05	0.00195	CbGpPWpGaD
Enzalutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.5e-05	0.00194	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL10—multiple sclerosis	7.42e-05	0.00192	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	7.42e-05	0.00192	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—multiple sclerosis	7.36e-05	0.0019	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—multiple sclerosis	7.29e-05	0.00188	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—STAT3—multiple sclerosis	7.27e-05	0.00188	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—U2AF2—multiple sclerosis	7.26e-05	0.00188	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—HNRNPA1—multiple sclerosis	7.26e-05	0.00188	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL4—multiple sclerosis	7.22e-05	0.00186	CbGpPWpGaD
Enzalutamide—CYP2B6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.18e-05	0.00186	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—IFNG—multiple sclerosis	7.06e-05	0.00183	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	7.05e-05	0.00182	CbGpPWpGaD
Enzalutamide—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	7.02e-05	0.00181	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—CCL2—multiple sclerosis	6.76e-05	0.00175	CbGpPWpGaD
Enzalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.69e-05	0.00173	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—FAS—multiple sclerosis	6.65e-05	0.00172	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	6.61e-05	0.00171	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—PGR—multiple sclerosis	6.56e-05	0.0017	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	6.54e-05	0.00169	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—IL1B—multiple sclerosis	6.3e-05	0.00163	CbGpPWpGaD
Enzalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.16e-05	0.00159	CbGpPWpGaD
Enzalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.1e-05	0.00158	CbGpPWpGaD
Enzalutamide—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.08e-05	0.00157	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—ICAM1—multiple sclerosis	6e-05	0.00155	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	5.97e-05	0.00154	CbGpPWpGaD
Enzalutamide—ALB—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	5.84e-05	0.00151	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IFNG—multiple sclerosis	5.75e-05	0.00149	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—ZFP36L1—multiple sclerosis	5.74e-05	0.00148	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	5.61e-05	0.00145	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	5.54e-05	0.00143	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CD80—multiple sclerosis	5.52e-05	0.00143	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.51e-05	0.00142	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.51e-05	0.00142	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	5.48e-05	0.00142	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	5.48e-05	0.00142	CbGpPWpGaD
Enzalutamide—CYP2C19—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.43e-05	0.0014	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—CCL2—multiple sclerosis	5.37e-05	0.00139	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IL1B—multiple sclerosis	5.13e-05	0.00132	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IL2—multiple sclerosis	5.11e-05	0.00132	CbGpPWpGaD
Enzalutamide—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.99e-05	0.00129	CbGpPWpGaD
Enzalutamide—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.95e-05	0.00128	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.92e-05	0.00127	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.92e-05	0.00127	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	4.91e-05	0.00127	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PLEK—multiple sclerosis	4.91e-05	0.00127	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	4.78e-05	0.00123	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—VDR—multiple sclerosis	4.59e-05	0.00119	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—TNF—multiple sclerosis	4.57e-05	0.00118	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IFNG—multiple sclerosis	4.57e-05	0.00118	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.49e-05	0.00116	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.49e-05	0.00116	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PABPC1—multiple sclerosis	4.45e-05	0.00115	CbGpPWpGaD
Enzalutamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	4.44e-05	0.00115	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—MYC—multiple sclerosis	4.43e-05	0.00114	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	4.36e-05	0.00113	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—MAPK1—multiple sclerosis	4.33e-05	0.00112	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	4.25e-05	0.0011	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—SRM—multiple sclerosis	4.12e-05	0.00106	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IL1B—multiple sclerosis	4.07e-05	0.00105	CbGpPWpGaD
Enzalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	4.03e-05	0.00104	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—SRM—multiple sclerosis	4.02e-05	0.00104	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—TNF—multiple sclerosis	4.02e-05	0.00104	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—RPL5—multiple sclerosis	4.01e-05	0.00104	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	3.89e-05	0.00101	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—IL2—multiple sclerosis	3.88e-05	0.001	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	3.83e-05	0.000991	CbGpPWpGaD
Enzalutamide—CYP2B6—Biological oxidations—POMC—multiple sclerosis	3.81e-05	0.000986	CbGpPWpGaD
Enzalutamide—CYP3A5—Biological oxidations—POMC—multiple sclerosis	3.73e-05	0.000964	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	3.72e-05	0.000962	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TNF—multiple sclerosis	3.72e-05	0.000961	CbGpPWpGaD
Enzalutamide—ALB—Vitamin B12 Metabolism—IL6—multiple sclerosis	3.69e-05	0.000954	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.67e-05	0.000948	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.66e-05	0.000946	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.59e-05	0.000928	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—SRM—multiple sclerosis	3.48e-05	0.0009	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—SRM—multiple sclerosis	3.46e-05	0.000895	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SELE—multiple sclerosis	3.46e-05	0.000894	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.42e-05	0.000883	CbGpPWpGaD
Enzalutamide—ALB—Platelet degranulation—TGFB1—multiple sclerosis	3.42e-05	0.000883	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—AQP4—multiple sclerosis	3.36e-05	0.000868	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—IL2RA—multiple sclerosis	3.31e-05	0.000856	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	3.28e-05	0.000848	CbGpPWpGaD
Enzalutamide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	3.26e-05	0.000843	CbGpPWpGaD
Enzalutamide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	3.25e-05	0.000841	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—IL6—multiple sclerosis	3.24e-05	0.000838	CbGpPWpGaD
Enzalutamide—CYP2C8—Biological oxidations—POMC—multiple sclerosis	3.23e-05	0.000835	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PGR—multiple sclerosis	3.16e-05	0.000817	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—SRM—multiple sclerosis	3.11e-05	0.000804	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—SRM—multiple sclerosis	3.04e-05	0.000785	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	3.02e-05	0.000781	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—IL6—multiple sclerosis	3e-05	0.000776	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.97e-05	0.000767	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	2.96e-05	0.000764	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	2.94e-05	0.00076	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYP24A1—multiple sclerosis	2.9e-05	0.000749	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CYP27B1—multiple sclerosis	2.9e-05	0.000749	CbGpPWpGaD
Enzalutamide—CYP2C19—Biological oxidations—POMC—multiple sclerosis	2.88e-05	0.000745	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—SRM—multiple sclerosis	2.86e-05	0.000739	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—SRM—multiple sclerosis	2.84e-05	0.000733	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	2.83e-05	0.000732	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	2.83e-05	0.000732	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—TNF—multiple sclerosis	2.82e-05	0.00073	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—GPC5—multiple sclerosis	2.65e-05	0.000685	CbGpPWpGaD
Enzalutamide—CYP2D6—Biological oxidations—POMC—multiple sclerosis	2.65e-05	0.000685	CbGpPWpGaD
Enzalutamide—CYP2C9—Biological oxidations—POMC—multiple sclerosis	2.63e-05	0.000679	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	2.6e-05	0.000672	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—GPC5—multiple sclerosis	2.59e-05	0.00067	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—ITGA4—multiple sclerosis	2.5e-05	0.000646	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IFNB1—multiple sclerosis	2.48e-05	0.000641	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	2.45e-05	0.000634	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	2.45e-05	0.000634	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYP27B1—multiple sclerosis	2.44e-05	0.000631	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CYP24A1—multiple sclerosis	2.44e-05	0.000631	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.4e-05	0.00062	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.39e-05	0.000617	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	2.38e-05	0.000616	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—GPC5—multiple sclerosis	2.25e-05	0.00058	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—GPC5—multiple sclerosis	2.23e-05	0.000577	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—VDR—multiple sclerosis	2.21e-05	0.000571	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—RRM1—multiple sclerosis	2.2e-05	0.000568	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYP24A1—multiple sclerosis	2.19e-05	0.000566	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CYP27B1—multiple sclerosis	2.19e-05	0.000566	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—RRM1—multiple sclerosis	2.15e-05	0.000555	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.14e-05	0.000553	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP24A1—multiple sclerosis	2.14e-05	0.000553	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CYP27B1—multiple sclerosis	2.14e-05	0.000553	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.02e-05	0.000521	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.02e-05	0.000521	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—GPC5—multiple sclerosis	2e-05	0.000518	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	2e-05	0.000516	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	2e-05	0.000516	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—GPC5—multiple sclerosis	1.96e-05	0.000506	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.95e-05	0.000505	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	1.94e-05	0.000502	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—SRM—multiple sclerosis	1.87e-05	0.000483	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—RRM1—multiple sclerosis	1.86e-05	0.000481	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—RRM1—multiple sclerosis	1.85e-05	0.000478	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—GPC5—multiple sclerosis	1.84e-05	0.000476	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—GPC5—multiple sclerosis	1.83e-05	0.000472	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—MYC—multiple sclerosis	1.82e-05	0.000471	CbGpPWpGaD
Enzalutamide—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.73e-05	0.000448	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL2RA—multiple sclerosis	1.71e-05	0.000441	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—RRM1—multiple sclerosis	1.66e-05	0.000429	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—RRM1—multiple sclerosis	1.62e-05	0.000419	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.53e-05	0.000395	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.52e-05	0.000392	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—RRM1—multiple sclerosis	1.51e-05	0.000391	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.5e-05	0.000386	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.49e-05	0.000386	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.49e-05	0.000384	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.46e-05	0.000378	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.44e-05	0.000373	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.44e-05	0.000371	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	1.39e-05	0.00036	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.32e-05	0.000341	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.32e-05	0.000341	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.29e-05	0.000333	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—BCHE—multiple sclerosis	1.26e-05	0.000326	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.24e-05	0.00032	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—BCHE—multiple sclerosis	1.23e-05	0.000319	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.23e-05	0.000319	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.21e-05	0.000311	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.17e-05	0.000304	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.13e-05	0.000292	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.11e-05	0.000286	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.07e-05	0.000276	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—BCHE—multiple sclerosis	1.06e-05	0.000275	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.01e-05	0.000261	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.01e-05	0.000261	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—IL2—multiple sclerosis	1e-05	0.000259	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—RRM1—multiple sclerosis	9.99e-06	0.000258	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—BCHE—multiple sclerosis	9.54e-06	0.000246	CbGpPWpGaD
Enzalutamide—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.36e-06	0.000242	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—BCHE—multiple sclerosis	9.31e-06	0.000241	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.2e-06	0.000238	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MYC—multiple sclerosis	8.78e-06	0.000227	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—BCHE—multiple sclerosis	8.77e-06	0.000227	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—BCHE—multiple sclerosis	8.7e-06	0.000225	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TGFB1—multiple sclerosis	7.81e-06	0.000202	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—MAPK1—multiple sclerosis	7.66e-06	0.000198	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—APOE—multiple sclerosis	7.59e-06	0.000196	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—APOE—multiple sclerosis	7.42e-06	0.000192	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—POMC—multiple sclerosis	6.52e-06	0.000169	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—APOE—multiple sclerosis	6.43e-06	0.000166	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—APOE—multiple sclerosis	6.39e-06	0.000165	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—POMC—multiple sclerosis	6.38e-06	0.000165	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ALB—multiple sclerosis	5.95e-06	0.000154	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ALB—multiple sclerosis	5.81e-06	0.00015	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—APOE—multiple sclerosis	5.74e-06	0.000148	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—BCHE—multiple sclerosis	5.74e-06	0.000148	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—APOE—multiple sclerosis	5.6e-06	0.000145	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—POMC—multiple sclerosis	5.52e-06	0.000143	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—POMC—multiple sclerosis	5.49e-06	0.000142	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—APOE—multiple sclerosis	5.28e-06	0.000136	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—APOE—multiple sclerosis	5.23e-06	0.000135	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ALB—multiple sclerosis	5.03e-06	0.00013	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—POMC—multiple sclerosis	4.93e-06	0.000127	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—POMC—multiple sclerosis	4.81e-06	0.000124	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—POMC—multiple sclerosis	4.53e-06	0.000117	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—POMC—multiple sclerosis	4.49e-06	0.000116	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ALB—multiple sclerosis	4.49e-06	0.000116	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ALB—multiple sclerosis	4.39e-06	0.000113	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ALB—multiple sclerosis	4.13e-06	0.000107	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ALB—multiple sclerosis	4.1e-06	0.000106	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—APOE—multiple sclerosis	3.45e-06	8.92e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—POMC—multiple sclerosis	2.96e-06	7.66e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ALB—multiple sclerosis	2.7e-06	6.98e-05	CbGpPWpGaD
